Information Provided By:
Fly News Breaks for January 17, 2020
TGTX
Jan 17, 2020 | 07:08 EDT
H.C. Wainwright analyst Edward White raised his price target for TG Therapeutics to $24 from $20 after the company initiated a rolling new drug application submission to the FDA for accelerated approval of umbralisib for the treatment of previously treated marginal zone lymphoma and follicular lymphoma. This news is positive considering the inclusion of follicular lymphoma should ultimately lead to a less expensive and quicker process compared to two separate submissions, says the analyst. He keeps a Buy rating on TG Therapeutics.
News For TGTX From the Last 2 Days
There are no results for your query TGTX